Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) Director Buys 410,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Michael Stansky purchased 410,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $1,025,000.00. Following the transaction, the director owned 1,240,722 shares of the company’s stock, valued at $3,101,805. The trade was a 49.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock traded up $0.35 during mid-day trading on Monday, hitting $3.03. The company’s stock had a trading volume of 773,435 shares, compared to its average volume of 276,402. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. The stock has a market capitalization of $185.77 million, a P/E ratio of -2.15 and a beta of 0.56. TriSalus Life Sciences, Inc. has a twelve month low of $2.20 and a twelve month high of $7.95. The stock’s fifty day moving average price is $4.18 and its two-hundred day moving average price is $5.13.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. Research analysts forecast that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC purchased a new position in shares of TriSalus Life Sciences during the 1st quarter valued at $20,267,000. Nantahala Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 1.5% during the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after acquiring an additional 30,582 shares in the last quarter. Wasatch Advisors LP purchased a new position in shares of TriSalus Life Sciences during the 1st quarter valued at $5,752,000. Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after acquiring an additional 345,186 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its holdings in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TLSI. Weiss Ratings cut shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Lake Street Capital lowered their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group lowered their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.50.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.